UK-ADC Publications

Alzheimer's disease 2005-2010

  1. Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, Patel ES, Baig I, Murphy MP, LeVine H, 3rd, Kraner SD, Norris CM. Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci 29: 12957-12969, 2009. PMCID2782445

  2. Abdul MH FJ, Sama MA, Mathis DM, Norris CM. NFATs and Alzheimer’s disease. Molecular and Cellular Pharmacology 2: 7-14, 2010. PMCID184535

  3. Abdul MH, Baig I, Levine, H III, Guttmann RP, Norris CM. Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric Abeta. Aging Cell: 2010, in press. PMC Journal- In Process

  4. Abner EL, Mendiondo MS. Using the SAS/Graph Annotate Facility to create timeline plots. Proc. 16th annual Southeast SAS Users Group, 2008.

  5. Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP. BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem 112: 1045-1053, 2010. PMCID2819564

  6. Aluise CD, Robinson RA, Beckett TL, Murphy MP, Cai J, Pierce WM, Markesbery WR, Butterfield DA. Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis 39: 221-228, 2010. PMCID2885559

  7. Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 69: 155-167, 2010. PMCID2826839

  8. Ashford JW, Borson S, O'Hara R, Dash P, Frank L, Robert P, Shankle WR, Tierney MC, Brodaty H, Schmitt FA, Kraemer HC, Buschke H. Should older adults be screened for dementia? Alzheimers Dement 2: 76-85, 2006.

  9. Bader Lange ML, Cenini G, Piroddi M, Mohmmad Abdul H, Sultana R, Galli F, Memo M, Butterfield DA. Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Dis 29: 456-464, 2008. PMCID2292396

  10. Bing G, Nguyen XV, Liu M, Markesbery WR, Sun A. Biophysical and biochemical characterization of the intrinsic fluorescence from neurofibrillary tangles. Neurobiol Aging 27:823-830, 2006.

  11. Bishop AJ, Martin P, MacDonald M, Poon L, Jazwinski SM, Green RC, Gearing M, Markesbery WR, Woodard JL, Johnson MA, Tenover JS, Siegler IC, Rodgers WL, Hausman DB, Rott C, Davey A, Arnold J. Predicting happiness among centenarians. Gerontology 56: 88-92, 2010. PMCID2874733

  12. Bottiggi KA, Chang JJ, Schmitt FA, Avison MJ, Mootoor Y, Nath A, Berger JR. The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci 260: 11-15, 2007.

  13. Bottiggi KA, Salazar JC, Yu L, Caban-Holt AM, Ryan M, Schmitt FA. Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. Am J Geriatr Psychiatry 15: 357-359, 2007.

  14. Bottiggi KA, Salazar JC, Yu L, Caban-Holt AM, Ryan M, Mendiondo MS, Schmitt FA. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 14: 980-984, 2006.

  15. Bradley MA, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med 48: 1570-1576, 2010. PMCID2881698

  16. Brown MR, Sullivan PG, Geddes JW. Synaptic mitochondria are more susceptible to Ca2+overload than nonsynaptic mitochondria. J Biol Chem 281:11658-11668, 2006.

  17. Bruce-Keller AJ, Gupta S, Parrino TE, Knight AG, Ebenezer PJ, Weidner AM, LeVine H, 3rd, Keller JN, Markesbery WR. NOX activity is increased in mild cognitive impairment. Antioxid Redox Signal 12: 1371-1382, 2009. PMCID2864654

  18. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, Sultana R. Pin1 in Alzheimer's disease. J Neurochem 98:1697-1706, 2006.

  19. Butterfield DA, Bader Lange ML, Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta: 02/24/2010 [Epub ahead of print]. PMCID182231

  20. Butterfield DA, Hardas SS, Lange ML. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's Disease: many pathways to neurodegeneration. J Alzheimers Dis: 02/19/2010 [Epub ahead of print]. PMCID292298

  21. Butterfield DA, Lange ML. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem 111: 915-933, 2009. PMC Journal- In Process

  22. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22:223-232, 2006.

  23. Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 43: 658-677, 2007.

  24. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, Sultana R. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 397:170-173, 2006.

  25. Butterfield DA, Reed TT, Perluigi M, De Marco C, Coccia R, Keller JN, Markesbery WR, Sultana R. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 1148: 243-248, 2007.

  26. Butterfield DA, Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis 12: 61-72, 2007.

  27. Caban-Holt A, Bottiggi K, Schmitt FA. Measuring treatment response in Alzheimer's disease clinical trials. Geriatrics Suppl: 3-8, 2005.

  28. Caban-Holt A, Mattingly M, Cooper G, Schmitt FA. Neurodegenerative memory disorders: a potential role of environmental toxins. Neurol Clin 23: 485-521, 2005.

  29. Caggiano DM, Jiang Y, Parasuraman R. Aging and repetition priming for targets and distracters in a working memory task. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 13: 552-573, 2006.

  30. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, Butterfield DA. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 8:1975-1986, 2006.

  31. Camicioli R, Kryscio R. Nature throws curveballs: APOE and nonlinear decline in Alzheimer disease. Neurology 65: 1855-1856, 2005.

  32. Campbell KH, Stocking CB, Hougham GW, Whitehouse PJ, Danner DD, Sachs GA. Dementia, diagnostic disclosure, and self-reported health status. J Am Geriatr Soc 56: 296-300, 2008.

  33. Carr SA, Davis R, Spencer D, Smart M, Hudson J, Freeman S, Cooper GE, Schmitt FA, Markesbery WR, Danner D, Jicha GA. Comparison of recruitment efforts targeted at primary care physicians versus the community at large for participation in Alzheimer disease clinical trials. Alzheimer Dis Assoc Disord 24: 165-170, 2009. PMCID2877762

  34. Cecarini V, Ding Q, Keller JN. Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radic Res 41: 673-680, 2007.

  35. Cenini G, Sultana R, Memo M, Butterfield DA. Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease. Free Radic Biol Med 45: 81-85, 2008. PMCID2587421

  36. Cenini G, Sultana R, Memo M, Butterfield DA. Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. J Cell Mol Med 12: 987-994, 2008.

  37. Chen Q, Wang S, Thompson SN, Hall ED, Guttmann RP. Identification and characterization of PEBP as a calpain substrate. J Neurochem 99: 1133-1141, 2006. PMID 17018026

  38. Cooper G, Schmitt F. Field guide to mental status testing. Practical Neurology 4(1): 68-73, 2005.

  39. Corneveaux JJ, Liang WS, Reiman EM, Webster JA, Myers AJ, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Craig DW, Coon KD, Dunckley T, Bandy D, Lee W, Chen K, Beach TG, Mastroeni D, Grover A, Ravid R, Sando SB, Aasly JO, Heun R, Jessen F, Kolsch H, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Papassotiropoulos A, Stephan DA, Huentelman MJ. Evidence for an association between KIBRA and late-onset Alzheimer's disease. Neurobiol Aging 31: 901-909, 2010. PMCID2913703

  40. Cuellar TL, Davis TH, Nelson PT, Loeb GB, Harfe BD, Ullian E, McManus MT. Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration. Proc Natl Acad Sci U S A 105: 5614-5619, 2008. PMCID2291142

  41. Danner D, McGuire, C. An evaluation of the Best Friends approach in adult day care. Alzheimers care today, 11 (4) 2010, In press. PMC Journal- in Process

  42. Danner DD, Smith CD, Jessa P, Hudson J. African Americans with memory loss: findings from a community clinic in Lexington, Kentucky. Nurs Clin North Am 43: 437-447, 2008. PMCID2565494

  43. Dassel KB, Schmitt FA. The impact of caregiver executive skills on reports of patient functioning. Gerontologist 48: 781-792, 2008.

  44. Dasuri K, Ebenezer P, Zhang L, Fernandez-Kim SO, Bruce-Keller AJ, Markesbery WR, Keller JN. Increased protein hydrophobicity in response to aging and Alzheimer disease. Free Radic Biol Med 48: 1330-1337, 2010. NIHMS182072

  45. Di Domenico F, Cenini G, Sultana R, Perluigi M, Uberti D, Memo M, Butterfield DA. Glutathionylation of the pro-apoptotic protein p53 in Alzheimer's disease brain: implications for AD pathogenesis. Neurochem Res 34: 727-733, 2009. PMCID2810644

  46. Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, Cini C, Butterfield DA. Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res 1333: 72-81, 2010. PMCID: 2871982.

  47. Dieter LS, Estus S. Isoform of APOE with retained intron 3; quantitation and identification of an associated single nucleotide polymorphism. Molec Neurodeg: 2010, in press. PMC Journal-In Process

  48. Ding Q, Keller JN. Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci Lett 373: 67-72, 2005.

  49. Ding Q, Markesbery WR, Cecarini V, Keller JN. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem Res 31:705-710, 2006.

  50. Ding Q, Markesbery WR, Chen Q, Li F, Keller JN. Ribosome dysfunction is an early event in Alzheimer's disease. J Neurosci 25: 9171-9175, 2005.

  51. Dong J, Robertson JD, Markesbery WR, Lovell MA. Serum zinc in the progression of Alzheimer's disease. J Alzheimers Dis 15: 443-450, 2008. PMCID2683420

  52. Ertekin-Taner N, Ronald J, Feuk L, Prince J, Tucker M, Younkin L, Hella M, Jain S, Hackett A, Scanlin L, Kelly J, Kihiko-Ehman M, Neltner M, Hersh L, Kindy M, Markesbery W, Hutton M, de Andrade M, Petersen RC, Graff-Radford N, Estus S, Brookes AJ, Younkin SG. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet 14: 447-460, 2005.

  53. Espinosa PS, Kryscio RJ, Mendiondo MS, Schmitt FA, Wekstein DR, Markesbery WR, Smith CD. Alzheimer's disease and head circumference. J Alzheimers Dis 9:77-80, 2006.

  54. Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 20: 263-268, 2006.

  55. Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao G, Nelson PT. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol: 08/04/2010 [Epub ahead of print] . PMC Journal- in Process

  56. Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA, Jhaveri BS, Karlawish JH, Pestronk A, Smith TW, Tu PH, Watts GD, Markesbery WR, Smith CD, Kimonis VE. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol: 65:571-581, 2006.

  57. Galasko D, Schmitt F, Thomas R, JIin S, Bennett D, Ferris S. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. JINS: 446–453, 2005.

  58. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 21: 292-299, 2007.

  59. Gaugler JE, Anderson KA, Leach MS, Smith CD, Schmitt FA, Mendiondo M. The emotional ramifications of unmet need in dementia caregiving. Am J Alzheimers Dis Other Demen 19: 369-380, 2005.

  60. Giannattasio C, Poleggi A, Puopolo M, Pocchiari M, Antuono P, Dal Forno G, Wekstein DR, Matera MG, Seripa D, Acciarri A, Bizzarro A, Lauria A, Masullo C. Survival in Alzheimer's disease is shorter in women carrying heterozygosity at codon 129 of the PRNP gene and no APOE epsilon 4 allele. Dement Geriatr Cogn Disord 25: 354-358, 2008.

  61. Gold BT, Andersen AH, Jicha GA, Smith CD. Aging influences the neural correlates of lexical decision but not automatic semantic priming. Cereb Cortex 19: 2671-2679, 2009. PMCID2758680

  62. Gold BT, Balota DA, Jones SJ, Powell DK, Smith CD, Andersen AH. Dissociation of automatic and strategic lexical-semantics: functional magnetic resonance imaging evidence for differing roles of multiple frontotemporal regions. J Neurosci 26:6523-6532, 2006.

  63. Gold BT, Jiang Y, Jicha GA, Smith CD. Functional response in ventral temporal cortex differentiates mild cognitive impairment from normal aging. Hum Brain Mapp 31: 1249-1259, 2010. NIHMS222268

  64. Gold BT, Powell DK, Andersen AH, Smith CD. Alterations in multiple measures of white matter integrity in normal women at high risk for Alzheimer's disease. Neuroimage 52: 1487-1494, 2010. PMCID: 2910213

  65. Gold BT, Powell DK, Xuan L, Jiang Y, Hardy PA. Speed of lexical decision correlates with diffusion anisotropy in left parietal and frontal white matter: evidence from diffusion tensor imaging. Neuropsychologia 45: 2439-2446, 2007.

  66. Gold BT, Powell DK, Xuan L, Jicha GA, Smith CD. Age-related slowing of task switching is associated with decreased integrity of frontoparietal white matter. Neurobiol Aging 31: 512-522, 2010. PMCID2815097

  67. Gold BT, Powell DK, Xuan L, Jicha GA, Smith CD. Age-related slowing of task switching is associated with decreased integrity of frontoparietal white matter. Neurobiol Aging 31: 512-522, 2010. PMCID2815097

  68. Gopalraj RK, Zhu H, Kelly JF, Mendiondo M, Pulliam JF, Bennett DA, Estus S. Genetic association of low density lipoprotein receptor and Alzheimer's disease. Neurobiol Aging 26: 1-7, 2005.

  69. Grear KE, Ling IF, Simpson JF, Furman JL, Simmons CR, Peterson SL, Schmitt FA, Markesbery WR, Liu Q, Crook JE, Younkin SG, Bu G, Estus S. Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain. Mol Neurodegener 4: 46, 2009. PMCID2776013

  70. Guo C, Lawson AL, Jiang Y. Distinct neural mechanisms for repetition effects of visual objects. Neuroscience 149: 747-759, 2007. PMCID2203616

  71. Guo C, Lawson AL, Zhang Q, Jiang Y. Brain potentials distinguish new and studied objects during working memory. Hum Brain Mapp 29: 441-452, 2008.

  72. Hensley B, Martin P, MacDonald M, Poon L, Jazwinski SM, Green RC, Gearing M, Markesbery WR, Woodard JL, Johnson MA, Tenover JS, Siegler IC, Rodgers WL, Hausman DB, Rott C, Davey A, Arnold J. Family history and adaptation among centenarians and octogenarians. Gerontology 56: 83-87, 2010. PMCID2874732

  73. Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM, Weiner M, Thal L, Petersen R, Jack CR, Jr., Jagust W, Trojanowki J, Toga AW, Beckett L, Green RC, Gamst A, Potter WZ, Montine T, Anders D, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Harvey D, Kornak J, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Vorobik R, Quinn J, Schneider L, Pawluczyk S, Spann B, Fleisher AS, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Mintun MA, Schneider S, Marson D, Griffith R, Badger B, Grossman H, Tang C, Stern J, Detoledo-Morrell L, Shah RC, Bach J, Duara R, Isaacson R, Strauman S, Albert MS, Pedroso J, Toroney J, Rusinek H, de Leon MJ, De Santi SM, Doraiswamy PM, Petrella JR, Aiello M, Clark CM, Pham C, Nunez J, Smith CD, Given CA, 2nd, Hardy P, Dekosky ST, Oakley M, Simpson DM, Ismail MS, Porsteinsson A, McCallum C, Cramer SC, Mulnard RA, McAdams-Ortiz C, Diaz-Arrastia R, Martin-Cook K, Devous M, Levey AI, et al. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 106: 20954-20959, 2009. PMCID 2791580.

  74. Hong MG, Myers AJ, Magnusson PK, Prince JA. Transcriptome-wide assessment of human brain and lymphocyte senescence. PLoS ONE 3: e3024, 2008. PMCID2515343

  75. Hughes T, Tyler K, Danner D, Carter A. African American caregivers: An exploration of pathways and barriers to a diagnosis of Alzheimer’s disease for a family member with dementia. Dementia: the International Journal of Social Research and Practice 8: 95-116, 2009.

  76. Iacono D, Markesbery WR, Gross M, Pletnikova O, Rudow G, Zandi P, Troncoso JC. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 73: 665-673, 2009. PMCID287271

  77. Jiang Y, Vagnini V, Clark J, Zhang Q. Reduced sensitivity of older adults to affective mismatches. ScientificWorldJournal 7: 641-648, 2007.

  78. Jicha GA, Abner E, Schmitt FA, Cooper GE, Stiles N, Hamon R, Carr S, Smith CD, Markesbery WR. Clinical features of mild cognitive impairment differ in the research and tertiary clinic settings. Dement Geriatr Cogn Disord 26: 187-192, 2008. PMCID2667338

  79. Jicha GA, Carr SA. Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. J Alzheimers Dis 19: 253-272, 2010. PMCID2881218

  80. Jicha GA, Markesbery WR. Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease. Clinical Interventions in Aging 5: 45-61, 2010. PMCID285051

  81. Jicha GA, Parisi JE, Dickson DW, Cha RH, Johnson KA, Smith GE, Boeve BF, Petersen RC, Knopman DS. Age and apoE associations with complex pathologic features in Alzheimer's disease. J Neurol Sci 273: 34-39, 2008. PMCID2569823

  82. Jicha GA, Schmitt FA, Abner E, Nelson PT, Cooper GE, Smith CD, Markesbery WR. Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging: 11/26/2008 [Epub ahead of print]. PMCID105027

  83. Jicha GA. Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'? Expert Opin Biol Ther 9: 481-491, 2009. PMCID2704502

  84. Jo DG, Arumugam TV, Woo HN, Park JS, Tang SC, Mughal M, Hyun DH, Park JH, Choi YH, Gwon AR, Camandola S, Cheng A, Cai H, Song W, Markesbery WR, Mattson MP. Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease. Neurobiol Aging 31: 917-925, 2010. PMCID2858254

  85. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD, Arnold SE, Baldwin CT, Barber R, Beach T, Bigio EH, Bird TD, Boxer A, Burke JR, Cairns N, Carroll SL, Chui HC, Clark DG, Cotman CW, Cummings JL, Decarli C, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Gearing M, Geschwind DH, Ghetti B, Gilman S, Giordani B, Glass J, Graff-Radford NR, Green RC, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman A, Lopez OL, Mack WJ, Markesbery W, Marson DC, Martiniuk F, Masliah E, McKee AC, Mesulam M, Miller JW, Miller BL, Miller CA, Parisi JE, Perl DP, et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol, 2010. 2010/08/11. PMID 20697030.

  86. Kasarskis EJ, Mendiondo MS, Wells S, Malguizo MS, Thompson M, Healey M, Kryscio RJ. ALS Nutrition/NIPPV Study Group. The ALS Nutrition/NIPPV Study: Design, Feasibility, and Initial Results. Amyotrophic Lateral Sclerosis: in press, 2010.

  87. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64: 1152-1156, 2005.

  88. Keller JN. Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Res Rev 5: 1-13, 2006.

  89. Kimonis VE, Mehta SG, Fulchiero EC, Thomasova D, Pasquali M, Boycott K, Neilan EG, Kartashov A, Forman MS, Tucker S, Kimonis K, Mumm S, Whyte MP, Smith CD, Watts GD. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A 146A: 745-757, 2008. PMCID2467391

  90. Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, Erten-Lyons D, Kaye JA, Welsh-Bohmer KA, Troncoso JC, Markesbery WR, Petersen RC, Turner RS, Kukull WA, Bennett DA, Galasko D, Morris JC, Ott J. Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study. Neurobiol Aging: 05/11/2010 [Epub ahead of print]. NIHMS222479

  91. Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 66:828-832, 2006.

  92. Kryscio RJ, Schmitt, FA, Mendiondo, MS, Markesbery, WR. Hypertension as a risk factor for transitions from normal to dementia and mild cognitive impairment. In: Vellas B, Fitten L, Feldman H, Giacobini E, Grundman M, Winblad B and Kurz A (eds) Research and Practice in Alzheimer’s disease. Serdi Publishing, Paris, vol 12, pp 139-143, 2007.

  93. Kryscio RJ, Snowdon, D, Tyas, SL. Models for identifying risk factors for transitions from intact cognition to mild cognitive impairment and dementia. In JSM Proceedings, Statistical Computing Section. Alexandria, VA: American Statistical Association. pp 1394-1400, 2008.

  94. Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR. AD brain pathology: vascular origins? Results from the HAAS autopsy study. Neurobiol Aging 29: 1587-1590, 2008.

  95. Lawson AL, Guo C, Jiang Y. Age effects on brain activity during repetition priming of targets and distracters. Neuropsychologia 45: 1223-1231, 2007. PMCID1850388

  96. Levine H, 3rd, Walker LC. Molecular polymorphism of Abeta in Alzheimer's disease. Neurobiol Aging 31: 542-548, 2008. PMCID2842206

  97. Ling IF, Estus S. Role of SFRS13A in low density lipoprotein receptor splicing. Hum Mutat: 31: 702-709. PMC Journal- In Process

  98. Ling IF, Gopalraj RK, Simpson JF, Estus S. Expression and regulation of a low density lipoprotein receptor exon 12 splice variant. J Neurochem: 9/03/2010 [Epub ahead of print]. PMC Journal-In Process

  99. Liu M, Sun A, Shin EJ, Liu X, Kim SG, Runyons CR, Markesbery W, Kim HC, Bing G. Expression of microsomal epoxide hydrolase is elevated in Alzheimer's hippocampus and induced by exogenous beta-amyloid and trimethyi-tin. Eur J Neurosci 23:2027-2034, 2006. PMID: 16630050

  100. Liu Q, Zhang J, Tran H, Verbeek MM, Reiss K, Estus S, Bu G. LRP1 shedding in human brain: roles of ADAM10 and ADAM17. Mol Neurodegener 4: 17, 2009. PMCID2672942

  101. Liu X, Lovell MA, Lynn BC. Development of a method for quantification of acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue. Anal Chem 77: 5982-5989, 2005.

  102. Liu X, Lovell MA, Lynn BC. Detection and quantification of endogenous cyclic DNA adducts derived from trans-4-hydroxy-2-nonenal in human brain tissue by isotope dilution capillary liquid chromatography nano electrospray tandem mass spectrometry. Chem Res Toxicol 19:710-718, 2006.

  103. Locke DE, Fakhoury TA, Berry DT, Locke TR, Schmitt FA. Objective evaluation of personality and psychopathology in temporal lobe versus extratemporal lobe epilepsy. Epilepsy Behav 17: 172-177, 2010.

  104. Lovell MA, Geiger H, Van Zant GE, Lynn BC, Markesbery WR. Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain. Neurobiol Aging 27:909-917, 2006.

  105. Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, Markesbery WR. An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology 70: 2212-2218, 2008.

  106. Lovell MA, Markesbery WR. Ectopic expression of Musashi-1 in Alzheimer's disease and Pick's disease. J Neuropathol Exp Neurol 64: 1-6, 2005.

  107. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 85: 3036-3040, 2007.

  108. Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 35: 7497-7504, 2007. PMCID2190704

  109. Lovell MA, Markesbery WR. Oxidatively modified RNA in mild cognitive impairment. Neurobiol Dis 29: 169-175, 2008. PMCID2700659

  110. Lovell MA, Markesbery WR. Amyloid beta peptide, 4-hydroxynonenal and apoptosis. Curr Alzheimer Res 3:359-364, 2006.

  111. Lovell MA, Smith JL, Markesbery WR. Elevated zinc transporter-6 in mild cognitive impairment, Alzheimer disease, and pick disease. J Neuropathol Exp Neurol 65:489-498, 2006.

  112. Lovell MA, Smith JL, Xiong S, Markesbery WR. Alterations in zinc transporter protein-1 (ZnT-1) in the brain of subjects with mild cognitive impairment, early, and late-stage Alzheimer's disease. Neurotox Res 7:265-271, 2005.

  113. Lovell MA, Xiong S, Lyubartseva G, Markesbery WR. Organo-selenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. Free Radic Biol Med 46: 1527-1533, 2009. PMCID2683469

  114. Lovell MA, Xiong S, Markesbery WR, Lynn BC. Quantitative proteomic analysis of mitochondria from primary neuron cultures treated with amyloid beta peptide. Neurochem Res 30: 113-122, 2005.

  115. Lovell MA. A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease. J Alzheimers Dis 16: 471-483, 2009. PMCID2881701

  116. Lovell MA. Similarities and differences between mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 19: 219, 2010. PMC Journal- In Process

  117. Lynn BC, Wang J, Markesbery WR, Lovell MA. Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease. J Alzheimers Dis 19: 325-339, 2010. PMCID2905865

  118. Lyubartseva G, Smith JL, Markesbery WR, Lovell MA. Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol 20: 343-350, 2010. PMC-Journal in Process

  119. MacDonald M, Aneja A, Martin P, Margrett J, Poon LW, Jazwinski SM, Green RC, Gearing M, Markesbery WR, Woodard JL, Johnson MA, Tenover JS, Siegler IC, Rodgers WL, Hausman DB, Rott C, Davey A, Arnold J. Distal and proximal resource influences on economic dependency among the oldest old. Gerontology 56: 100-105, 2010. PMCID2874735

  120. Madathil SK, Nelson PT, Saatman KE, and Wilfred BR.  MicroRNAs in CNS injury: potential roles and therapeutic implications.  BioEssays: 2010, in press.

  121. Mao G, Pan X, Zhu BB, Zhang Y, Yuan F, Huang J, Lovell MA, Lee MP, Markesbery WR, Li GM, Gu L. Identification and characterization of OGG1 mutations in patients with Alzheimer's disease. Nucleic Acids Res 35: 2759-2766, 2007.

  122. Marcum JL, Mathenia JK, Chan R, Guttmann RP. Oxidation of thiol-proteases in the hippocampus of Alzheimer's disease. Biochem Biophys Res Commun 334: 342-348, 2005.

  123. Margrett J, Martin P, Woodard JL, Miller LS, MacDonald M, Baenziger J, Siegler IC, Davey A, Poon L, Jazwinski SM, Green RC, Gearing M, Markesbery WR, Johnson MA, Tenover JS, Rodgers WL, Hausman DB, Rott C, Arnold J. Depression among centenarians and the oldest old: contributions of cognition and personality. Gerontology 56: 93-99, 2010. PMCID2874734

  124. Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 68: 816-822, 2009. PMCID2704264

  125. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58: 730-735, 2005.

  126. Markesbery WR, Lovell MA. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol 64: 954-956, 2007.

  127. Markesbery WR, Lovell MA. DNA oxidation in Alzheimer's disease. Antioxid Redox Signal 8:2039-2045, 2006.

  128. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63:38-46, 2006.

  129. Markesbery WR. Commentary on "Vascular cognitive impairment: Today and tomorrow". Alzheimer's and Dementia 2: 205-206, 2006.

  130. Markesbery WR. Neuropathologic alterations in mild cognitive impairment: a review. J Alzheimers Dis 19: 221-228, 2010. PMCID2872776

  131. Martin SB, Covell DJ, Joseph JE, Chebrolu H, Smith CD, Kelly TH, Jiang Y, Gold BT. Human experience seeking correlates with hippocampus volume: convergent evidence from manual tracing and voxel-based morphometry. Neuropsychologia 45: 2874-2881, 2007.

  132. Martin SB, Smith CD, Collins HR, Schmitt FA, Gold BT. Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment. Neurobiol Aging 31: 1099-1106, 2010. PMCID2873058

  133. Mehta SG, Watts GD, Adamson JL, Hutton M, Umberger G, Xiong S, Ramdeen S, Lovell MA, Kimonis VE, Smith CD. APOE is a potential modifier gene in an autosomal dominant form of frontotemporal dementia (IBMPFD). Genet Med 9: 9-13, 2007.

  134. Mitchell DB, Schmitt FA. Short- and long-term implicit memory in aging and Alzheimer's disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 13:611-635, 2006.

  135. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 7: 269-275, 2005.

  136. Mortimer JA, Snowdon DA, Markesbery WR. Small head circumference is associated with less education in persons at risk for Alzheimer disease in later life. Alzheimer Dis Assoc Disord 22: 249-254, 2008.

  137. Mortimer JA, Snowdon DA, Markesbery WR. The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord 23: 152-157, 2009. PMCID2752689

  138. Murphy MP, Ahmed RR, Webb RL, Holler CJ, Li F, Beckett TL, Niedowicz DM, Studzinski CM, Head E. Aging, Neurodegenerative Disease and β-Secretase. In: Fisher A and Hanin I (eds) New Trends in Alzheimer and Parkinson Related Disorders. Medimond International, Bologna, Italy, pp 65-65, 2009.

  139. Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H, 3rd, Keller JN. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 27: 301-311, 2007.

  140. Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, Marlowe L, Kaleem M, Leung D, Bryden L, Nath P, Zismann VL, Joshipura K, Huentelman MJ, Hu-Lince D, Coon KD, Craig DW, Pearson JV, Holmans P, Heward CB, Reiman EM, Stephan D, Hardy J. A survey of genetic human cortical gene expression. Nat Genet 39: 1494-1499, 2007.

  141. Nelson PT, Abner EL, Scheff SW, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Patel E, Markesbery WR. Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment. Neurosci Lett 450: 336-339, 2009. PMCID2839166

  142. Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Santacruz K, Smith CD, Patel E, Markesbery WR. Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol 68: 774-784, 2009. PMCID2725359

  143. Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Davis DG, Poduska JW, Patel E, Mendiondo MS, Markesbery WR. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 20: 66-79, 2008. PMCID2864342

  144. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68: 1-14, 2009. PMCID2692822

  145. Nelson PT, Dimayuga J, Wilfred BR. MicroRNA in Situ Hybridization in the Human Entorhinal and Transentorhinal Cortex. Front Hum Neurosci 4: 7, 2010. PMCID2831629

  146. Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, Xu LO, Smith CD, Markesbery WR. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 257: 359-366, 2010. PMCID2839040

  147. Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, Abner EL, Markesbery WR. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol 66: 1136-1146, 2007.

  148. Nelson PT, Keller JN. RNA in brain disease: no longer just "the messenger in the middle". J Neuropathol Exp Neurol 66: 461-468, 2007.

  149. Nelson PT, Kiriakidou M, Mourelatos Z, Tan GS, Jennings MH, Xie K, Wang WX. High-throughput experimental studies to identify miRNA targets directly, with special focus on the mammalian brain. Brain Res 1338: 122-130, 2010. PMCID2892778

  150. Nelson PT, Kryscio RJ, Abner EL, Schmitt FA, Jicha GA, Mendiondo MS, Cooper G, Smith CB, Markesbery WR. Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer's disease and AD + DLB. J Alzheimers Dis 16: 29-34, 2009. PMCID2682919

  151. Nelson PT, Kryscio RJ, Jicha GA, Abner EL, Schmitt FA, Xu LO, Cooper G, Smith CD, Markesbery WR. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology 73: 1127-1133, 2009. PMCID2764396

  152. Nelson PT, Kukull WA, Frosch MP. Thinking outside the box: Alzheimer-type neuropathology that does not map directly onto current consensus recommendations. J Neuropathol Exp Neurol 69: 449-454, 2010. PMCID2892786

  153. Nelson PT, Schmitt FA, Jicha GA, Kryscio RJ, Abner EL, Smith CD, Van Eldik LJ, Markesbery WR. Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol, 06/22/2010/[Epub ahead of print]

  154. Nelson PT, Smith CD, Abner EA, Schmitt FA, Scheff SW, Davis GJ, Keller JN, Jicha GA, Davis D, Wang-Xia W, Hartman A, Katz DG, Markesbery WR. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta 1792: 454-469, 2009. PMCID2834412

  155. Nelson PT, Wang WX, Rajeev BW. MicroRNAs (miRNAs) in Neurodegenerative Diseases. Brain Pathol 18: 130-138, 2008. PMCID2859437

  156. Nelson PT, Wang WX, Wilfred BR, Tang G. Technical variables in high-throughput miRNA expression profiling: much work remains to be done. Biochim Biophys Acta 1779: 758-765, 2008. PMCID2660892

  157. Nelson PT, Wang WX. MiR-107 is Reduced in Alzheimer's Disease Brain Neocortex: Validation Study. J Alzheimers Dis 21: 75-79, 2010. PMCID2910235

  158. Nelson PT, Wang WX. MiR-107 is Reduced in Alzheimer's Disease Brain Neocortex: Validation Study. J Alzheimers Dis 21: 75-79, 2010. PMCID: 2910235

  159. Nelson PT, Wilfred BR. In situ hybridization is a necessary experimental complement to microRNA (miRNA) expression profiling in the human brain. Neurosci Lett 466: 69-72, 2009. PMCID156727

  160. Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, Taylor JP, Kretzschmar HA, Kimonis VE, Forman MS. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 66:152-157, 2007.

  161. Newman SF, Sultana R, Perluigi M, Coccia R, Cai J, Pierce WM, Klein JB, Turner DM, Butterfield DA. An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J Neurosci Res 85:1506-1514, 2007.

  162. Niedowicz DM, Nelson PT, Murphy MP. Alzheimer’s disease: pathological mechanisms and recent insights. Curr Neuropharmacol: 2010, in press. PMC Journal-In Process

  163. Nukala VN, Singh IN, Davis LM, Sullivan PG. Cryopreservation of brain mitochondria: a novel methodology for functional studies. J Neurosci Methods 152: 48-54, 2006.

  164. Owen JB, Di Domenico F, Sultana R, Perluigi M, Cini C, Pierce WM, Butterfield DA. Proteomics-determined differences in the concanavalin-a-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. J Proteome Res 8: 471-482, 2009. PMCID2658606

  165. Perluigi MR, Sultana G, Cenini F, Di Domenico M, Memo WM, Pierce RCaDAB. Redox proteomics identification of HNE-modified brain proteins in Alzheimer's Disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics. Clinical Applications 3: 682-693. 2009. PMCID2843938

  166. Petrovitch H, Ross GW, He Q, Uyehara-Lock J, Markesbery W, Davis D, Nelson J, Masaki K, Launer L, White LR. Characterization of Japanese-American men with a single neocortical AD lesion type. Neurobiol Aging 29: 1448-1455, 2008. PMCID2613368

  167. Petrovitch H, Ross GW, Steinhorn SC, Abbott RD, Markesbery W, Davis D, Nelson J, Hardman J, Masaki K, Vogt MR, Launer L, White LR. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol 57: 98-103, 2005.

  168. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armirotti A, D'Arrigo C, Bachi A, Cattaneo A, Canale C, Torrassa S, Saido TC, Markesbery W, Gambetti P, Tabaton M. beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem 280: 34186-34192, 2005.

  169. Poleggi A, Bizzarro A, Acciarri A, Antuono P, Bagnoli S, Cellini E, Forno GD, Giannattasio C, Lauria A, Matera MG, Nacmias B, Puopolo M, Seripa D, Sorbi S, Wekstein DR, Pocchiari M, Masullo C. Codon 129 polymorphism of prion protein gene in sporadic Alzheimer's disease. Eur J Neurol 15: 173-178, 2008.

  170. Price JL, McKeel DW, Jr., Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30: 1026-1036, 2009. PMCID2737680

  171. Ramsey-Klawsnik H TP, Mendiondo MS, Abner EL, Cecil KA, Tooms MR. Sexual abuse of vulnerable adults in care facilities: Clinical findings and a research initiative. J Am Psychiatr Nurses Assoc 12: 332-339, 2007.

  172. Randall GK, Martin P, McDonald M, Poon LW, Jazwinski SM, Green RC, Gearing M, Markesbery WR, Woodard JL, Johnson MA, Tenover JS, Siegler IC, Rodgers WL, Hausman DB, Rott C, Davey A, Arnold J. Social resources and longevity: findings from the Georgia Centenarian Study. Gerontology 56: 106-111, 2010. PMCID2874736

  173. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis 30: 107-120, 2008.

  174. Reed TT, Pierce WM, Jr., Turner DM, Markesbery WR, Butterfield DA. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol Med 13: 2019-2029, 2009. PMCID2819643

  175. Reed TT, Pierce WM, Markesbery WR, Butterfield DA. Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res 1274: 66-76, 2009. PMC Journal- In Process

  176. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 63: 49-54, 2006.

  177. Riley KP, Snowdon DA, Desrosiers MF, Markesbery WR. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiol Aging 26: 341-347, 2005.

  178. Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, Markesbery WR, Hardman J, Masaki K, Launer L, White LR. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 21:2062-2067, 2006.

  179. Rowe WB, Blalock EM, Chen KC, Kadish I, Wang D, Barrett JE, Thibault O, Porter NM, Rose GM, Landfield PW. Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats. J Neurosci.; 27:3098-3110, 2007.

  180. Salazar JC, Schmitt FA, Yu L, Mendiondo MM, Kryscio RJ. Shared random effects analysis of multistate Markov models: application to a longitudinal study of transitions to dementia. Stat Med. 26:568-580, 2007.

  181. Saunders BA, Podzielinski I, Ware RA, Goodrich S, Desimone CP, Ueland FR, Seamon L, Ubellacker J, Pavlik EJ, Kryscio RJ, van Nagell JR, Jr. Risk of malignancy in sonographically confirmed septated cystic ovarian tumors. Gynecol Oncol: 06/18/2010 [Epub ahead of print].

  182. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68: 1501-1508, 2007.

  183. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27:1372-1384, 2006.

  184. Schmitt F, Ryan M, Cooper G. A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease. Expert Opin Drug Metab Toxicol 3: 135-141, 2007.

  185. Schmitt FA, Aarsland D, Bronnick KS, Meng X, Tekin S, Olin JT. Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. Am J Alzheimers Dis Other Demen 25: 407-413, 2010. PMC Journal – In Process

  186. Schmitt FA, Saxton JA, Xu Y, McRae T, Sun Y, Richardson S, Li H. A brief instrument to assess treatment response in the patient with advanced Alzheimer disease. Alzheimer Dis Assoc Disord 23: 377-383, 2009. PMC Journal- In Process

  187. Schmitt FA, van Dyck CH, Wichems CH, Olin JT. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord 20:255-262, 2006.

  188. Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim Care Companion J Clin Psychiatry 8:158-159, 2006.

  189. Schneider LS, Clark CM, Doody R, Ferris SH, Morris JC, Raman R, Reisberg B, Schmitt FA. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord 20:S124-138, 2006.

  190. Schneider LS, Raman R, Schmitt FA, Doody RS, Insel P, Clark CM, Morris JC, Reisberg B, Petersen RC, Ferris SH. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Dis Assoc Disord 23: 260-267, 2009. PMCID2762354

  191. Segerstrom SC, Roach AR, Evans DR, Schipper LJ. The structure and health correlates of trait repetitive thought in older adults. Psychology and Aging 2010. In press. PMC Journal- In Process

  192. Segerstrom SC, Schipper LJ, Greenberg RN. Caregiving, repetitive thought, and immune response to vaccination in older adults. Brain Behav Immun 22: 744-752, 2008. PMCID2464708

  193. Seripa D, Matera MG, Dal Forno G, Gravina C, Masullo C, Daniele A, Binetti G, Bonvicini C, Squitti R, Palermo MT, Davis DG, Antuono P, Wekstein DR, Dobrina A, Gennarelli M, Fazio VM. Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiol Aging 26: 455-464, 2005.

  194. Shao C, Xiong S, Li GM, Gu L, Mao G, Markesbery WR, Lovell MA. Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic Biol Med 45: 813-819, 2008. PMID: PMCID2745061

  195. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102: 216-222, 2005.

  196. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Research on Parkinson disease. J Neurosurg 102: 401, 2005.

  197. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 59: 473-477, 2005.

  198. Smith CD, Chebrolu H, Andersen AH, Powell DA, Lovell MA, Xiong S, Gold BT. White matter diffusion alterations in normal women at risk of Alzheimer's disease. Neurobiol Aging 31: 1122-1131, 2008. PMCID2873054

  199. Smith CD, Chebrolu H, Markesbery WR, Liu J. Improved predictive model for pre-symptomatic mild cognitive impairment and Alzheimer's disease. Neurol Res 30: 1091-1096, 2008.

  200. Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, Markesbery WR. Brain structural alterations before mild cognitive impairment. Neurology 68: 1268-1273, 2007.

  201. Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Markesbery WR. Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly. Neurobiol Aging 28: 1075-1087, 2007.

  202. Smith CD, Kryscio RJ, Schmitt FA, Lovell MA, Blonder LX, Rayens WS, Andersen AH. Longitudinal Functional Alterations in Asymptomatic Women at Risk for Alzheimer's Disease. J Neuroimaging 15: 271-277, 2005.

  203. Smith CD, Lori NF, Akbudak E, Sorar E, Gultepe E, Shimony JS, McKinstry RC, Conturo TE. MRI diffusion tensor tracking of a new amygdalo-fusiform and hippocampo-fusiform pathway system in humans. J Magn Reson Imaging 29: 1248-1261, 2009. PMCID2720528

  204. Smith CD, Walton A, Loveland AD, Umberger GH, Kryscio RJ, Gash DM. Memories that last in old age: motor skill learning and memory preservation. Neurobiol Aging 26: 883-890, 2005.

  205. Smith CD, Walton A, Slevin JT, Gerhardt GA, Umberger G, Smoot K, Schulze E, Gash D. Validation studies of the human movement analysis panel for hand/arm performance. J Neurosci Methods 165: 287-296, 2007.

  206. Smith CD, Wekstein DR, Markesbery WR, Frye CA. 3alpha,5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia. Psychopharmacology (Berl) 186:481-485, 2006.

  207. Smith CD. Mild cognitive impairment is too late: The case for presymtomatic detection and treatment for Alzheimer's disease. In: Sun M-K (ed) Cognitive Science Compendium. Nova Science Publishers, Inc., Hauppauge NY, Chapter 3, Vol 2, 2009.

  208. Smith CD. Neuroimaging through the course of Alzheimer's disease. J Alzheimers Dis 19: 273-290, 2010. PMC Journal- In Process

  209. Smith JL, Xiong S, Markesbery WR, Lovell MA. Altered expression of zinc transporters-4 and -6 in mild cognitive impairment, early and late Alzheimer's disease brain. Neuroscience 140:879-888, 2006. PMID: 16580781

  210. Sonnen JA, Breitner JC, Lovell MA, Markesbery WR, Quinn JF, Montine TJ. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med 45: 219-230, 2008. PMCID2459222

  211. Sparks DL, Kryscio RJ, Connor DJ, Sabbagh MN, Sparks LM, Lin Y, Liebsack C. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegener Dis 7: 183-186, 2010. PMCID2859238

  212. Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 5: 416-421, 2008.

  213. Stein PS, Desrosiers M, Donegan SJ, Yepes JF, Kryscio RJ. Tooth loss, dementia and neuropathology in the Nun study. J Am Dent Assoc 138: 1314-1322; quiz 1381-1312, 2007.

  214. Stein PS, Kryscio RJ, Desrosiers M, Donegan SJ, Gibbs MB. Tooth loss, apolipoprotein E, and decline in delayed word recall. J Dent Res 89: 473-477, 2010. PMCID2908403

  215. Stocking CB, Hougham GW, Danner DD, Patterson MB, Whitehouse PJ, Sachs GA. Speaking of research advance directives: planning for future research participation. Neurology 66:1361-1366, 2006.

  216. Stocking CB, Hougham GW, Danner DD, Patterson MB, Whitehouse PJ, Sachs GA. Empirical assessment of a research advance directive for persons with dementia and their proxies. J Am Geriatr Soc 55: 1609-1612, 2007.

  217. Sultana R, Banks WA, Butterfield DA. Decreased levels of PSD95 and two associated proteins and increased levels of BCl(2) and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease. J Neurosci Res 88: 469-447, 2010. PMCID185053

  218. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11: 153-164, 2007.

  219. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Zhou XZ, Lu KP, Butterfield DA. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiol Aging 27:918-925, 2006.

  220. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 27:1564-1576, 2006.

  221. Sultana R, Butterfield DA. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr 41: 441-446, 2009. PMCID2818870

  222. Sultana R, Butterfield DA. Regional expression of key cell cycle proteins in brain from subjects with amnestic mild cognitive impairment. Neurochem Res 32: 655-662, 2007.

  223. Sultana R, Butterfield DA. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 19: 341-353, 2010. PMC Journal- In Process

  224. Sultana R, Perluigi M, Butterfield DA. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 118: 131-150, 2009. PMCID2818870

  225. Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 8:2021-2037, 2006.

  226. Sultana R, Perluigi M, Newman SF, Pierce WM, Cini C, Coccia R, Butterfield DA. Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. Antioxid Redox Signal 12: 327-336, 2010. PMCID2821142

  227. Sultana R, Piroddi M, Galli F, Butterfield DA. Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33: 2540-2546, 2008.

  228. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 22:76-87, 2006.

  229. Sultana R, Reed T, Perluigi M, Coccia R, Pierce WM, Butterfield DA. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med 11: 839-851, 2007.

  230. Suzuki YJ, Carini M, Butterfield DA. Protein carbonylation. Antioxid Redox Signal 12: 323-325, 2009. PMCID2821144

  231. Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R. Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study. Brain 133: 1155-1162, 2010. PMC Journal- In Process

  232. Tang SC, Lathia JD, Selvaraj PK, Jo DG, Mughal MR, Cheng A, Siler DA, Markesbery WR, Arumugam TV, Mattson MP. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol 213: 114-121, 2008. PMCID2597513

  233. Teaster PB, Ramsey-Klawsnik H, Mendiondo MS, Abner E, Cecil K, Tooms M. From behind the shadows: a profile of the sexual abuse of older men residing in nursing homes. J Elder Abuse Negl 19: 29-45, 2007.

  234. Tyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS, Kryscio RJ. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol 165: 1231-1238, 2007.

  235. Tyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS, Kryscio RJ. Reply to comment. Am J Epidemiol, 165(11): 124, 2007.

  236. Van Dyck CH, Schmitt FA, Olin JT. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry 14:428-437, 2006.

  237. Wang CC, Yepes LC, Danaher RJ, Berger JR, Mootoor Y, Kryscio RJ, Miller CS. Low prevalence of varicella zoster virus and herpes simplex virus type 2 in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109: 232-237, 2010. PMCID2818125

  238. Wang J, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 96:825-832, 2006.

  239. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93: 953-962, 2005.

  240. Wang Q, Woltjer RL, Cimino PJ, Pan C, Montine KS, Zhang J, Montine TJ. Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J 19: 869-871, 2005.

  241. Wang W-X, Huang Q, Hu Y, Stromberg AJ, Nelson PT. Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: white matter versus gray matter. Acta Neuropathologica: Accepted, 2010. PMC Journal – In Process

  242. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28: 1213-1223, 2008. PMCID2837363

  243. Wang WX, Wilfred BR, Baldwin DA, Isett RB, Ren N, Stromberg A, Nelson PT. Focus on RNA isolation: obtaining RNA for microRNA (miRNA) expression profiling analyses of neural tissue. Biochim Biophys Acta 1779: 749-757, 2008. PMCID: 2650220

  244. Wang WX, Wilfred BR, Hu Y, Stromberg AJ, Nelson PT. Anti-Argonaute RIP-Chip shows that miRNA transfections alter global patterns of mRNA recruitment to microribonucleoprotein complexes. RNA 16: 394-404, 2010. PMCID2811668

  245. Wang WX, Wilfred BR, Madathil SK, Tang G, Hu Y, Dimayuga J, Stromberg AJ, Huang Q, Saatman KE, Nelson PT. miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. Am J Pathol 177: 334-345, 2010. PMCID2893676

  246. Wang WX, Wilfred BR, Xie K, Jennings MH, Hu Y, Stromberg AJ, Nelson PT. Individual microRNAs (miRNAs) display distinct mRNA targeting "rules". RNA Biol 7, 2010. PMC Journal - In Process

  247. Wang, W-X, Nelson PT, and Tang, G. RNA interference and miRNA pathways: mechanisms and protein machinery. In Wiley Encyclopedia of Chemical Biology. Editor: Tadhag P. Begley, John Wiley & Sons, Inc. NJ, January 2009. ISBN: 978-0-471-75477-0.

  248. Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, Hanson PI, Kimonis V, Pestronk A. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 79: 1186-1189, 2008. PMCID2586594

  249. Weissman L, Jo DG, Sorensen MM, de Souza-Pinto NC, Markesbery WR, Mattson MP, Bohr VA. Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Res 35: 5545-5555, 2007. PMCID2018628

  250. Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin 23: 1187-1197, 2007.

  251. White L, Small BJ, Petrovitch H, Ross GW, Masaki K, Abbott RD, Hardman J, Davis D, Nelson J, Markesbery W. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neural. 18:224-227, 2005.

  252. Wilfred BR, Wang WX, Nelson PT. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab 91: 209-217, 2007.

  253. Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 27:1094-1099, 2006.

  254. Wilson RS, Leurgans SE, Foroud TM, Sweet RA, Graff-Radford N, Mayeux R, Bennett DA. Telephone assessment of cognitive function in the late-onset Alzheimer's disease family study. Arch Neurol 67: 855-861, 2010.

  255. Woltjer RL, McMahan W, Milatovic D, Kjerulf JD, Shie FS, Rung LG, Montine KS, Montine TJ. Effects of chemical chaperones on oxidative stress and detergent-insoluble species formation following conditional expression of amyloid precursor protein carboxy-terminal fragment. Neurobiol Dis 25: 427-437, 2007.

  256. Xiong S, Markesbery WR, Shao C, Lovell MA. Seleno-L-methionine protects against beta-amyloid andiron/hydrogen peroxide-mediated neuron death. Antioxid Redox Signal 9:457-467, 2007.

  257. Xu L, Snowdon D, Kryscio RJ. A Markov transition model to dementia with death as a competing event. In: Proceedings Biometrics Section, Joint Statistical Meetings, Washington, D.C., pp 4671-4680, 2009.

  258. Yang J, Jicha G, Kryscio RJ, Schmitt F, Lipsky RH. Glutamate receptor gene GRIN2B and altered brain responses during working memory in older adults. NeuroImage suppl: in press, 2010. PMC Journal - In Process

  259. Youn H, Jeoung M, Koo Y, Ji H, Markesbery WR, Ji I, Ji TH. Kalirin is under-expressed in Alzheimer's disease hippocampus. J Alzheimers Dis 11: 385-397, 2007.

  260. Youn H, Ji I, Ji HP, Markesbery WR, Ji TH. Under-expression of Kalirin-7 Increases iNOS activity in cultured cells and correlates to elevated iNOS activity in Alzheimer's disease hippocampus. J Alzheimers Dis 12: 271-281, 2007.

  261. Yu L, Griffith WS, Tyas SL, Snowdon DA, Kryscio RJ. A nonstationary Markov transition model for computing the relative risk of dementia before death. Stat Med 29: 639-648, 2010. PMCID2830381

  262. Yu L, Tyas SL, Snowdon D, Kryscio RJ Effects of ignoring baseline on modeling transitions from intact cognition to dementia In: Proceedings of the Section on Epidemiology, Joint Statistical Meetings, Salt Lake City, UT. {CD-Rom} pp 134-140, 2007.

  263. Yu L, Tyas SL, Snowdon DA, Kryscio RJ. Effects of ignoring baseline on modeling transitions from intact cognition to dementia. Computational Statistics and Data Analysis 53:3334-3343, 2009. PMCID2703484

  264. Zhang Q, Lawson A, Quo C, Jiang Y. Electrophysiological correlates of visual affective priming. Brain Res Bull.; 71:316-323, 2006.

  265. Zou F, Gopalraj RK, Lok J, Zhu H, Ling IF, Simpson JF, Tucker HM, Kelly JF, Younkin SG, Dickson DW, Petersen RC, Graff-Radford NR, Bennett DA, Crook JE, Younkin SG, Estus S. Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease. Hum Mol Genet 17: 929-935, 2008. PMCID2361153